Medindia LOGIN REGISTER
Medindia
Advertisement

VioQuest Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference

Wednesday, October 31, 2007 General News
Advertisement
BASKING RIDGE, N.J., Oct. 31 VioQuestPharmaceuticals (OTC Bulletin Board: VQPH) today announced that DanielGreenleaf, President and Chief Executive Officer of VioQuest Pharmaceuticals,will be presenting at the Acumen BioFin Rodman & Renshaw 9th Annual HealthcareConference on Tuesday, November 6, at 12:00 p.m. EST at the Palace Hotel inNew York City. The conference is being held from November 5 - 7, 2007. Mr.Greenleaf will provide a company overview and update on the status ofVioQuest's current clinical development programs.
Advertisement

(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

Presentations by more than 350 emerging growth biotechnology companies areexpected at the Acumen BioFin Rodman & Renshaw 9th Annual HealthcareConference. Companies will share their accomplishments on an array oftherapeutic topics including oncology, cardiovascular disease, central nervoussystem disorders, infectious diseases, and medical device technology. Theevent will unite companies with institutional investors, venture capitalists,senior corporate executives, and experts from the scientific and medicalcommunities. The Conference will include company presentations, breakoutsessions, and one-on-one meetings with presenting companies.
Advertisement

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targetedlate preclinical and early clinical stage therapies with unique mechanisms ofaction primarily for oncology and infectious diseases. VioQuest has threetargeted drug candidates in clinical development: VQD-002 which inhibitsactivation of Akt that is seen at abnormally high levels in breast, ovarian,colorectal, pancreatic, and hematologic cancers; Lenocta(TM), an inhibitor ofspecific protein tyrosine phosphatases (PTPases), SHP-1 and SHP-2, which hasshown compelling clinical and biological activity in solid tumors andXyfid(TM), a topical therapy which has shown early clinical promise in thetreatment and prevention of chemo-induced Hand-Foot Syndrome (HFS). VioQuestanticipates commencing several Phase II trials for VQD-002, Lenocta(TM) andXyfid(TM) in the second half of 2007. In addition, VioQuest and the U.S. Armyare planning to submit a New Drug Application (NDA) to the U. S. Food and DrugAdministration (FDA) in 2007 for Lenocta(TM) for the treatment ofleishmaniasis.

Further information about VioQuest can be found at www.vioquestpharm.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risksand uncertainties that could cause VioQuest's actual results and experiencesto differ materially from the anticipated results and expectations expressedin these forward-looking statements. These statements are often, but notalways, made through the use of words or phrases such as anticipates, expects,plans, believes, intends, and similar words or phrases. These statements arebased on current expectations, forecasts and assumptions that are subject torisks and uncertainties, which could cause actual outcomes and results todiffer materially from these statements. In addition, this press release alsoincludes forward-looking statements regarding the timing, progress and resultsof the clinical development, regulatory processes, potential clinical trialinitiations, potential IND and NDA filings and commercialization efforts ofVioQuest's drug development product candidates. These statements are subjectto various risks and uncertainties and include the possibility that theresults of clinical trials will not support VioQuest's claims, the possibilitythat VioQuest's development efforts relating to its product candidates,including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, theinability to obtain regulatory approval of VioQuest's product candidates,VioQuest's reliance on third-party researchers to develop its productcandidates, its lack of experience in devel
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close